Context Therapeutics Inc

NASDAQ:CNTX   2:16:08 PM EDT
0.81
-0.18 (-18.21%)
Regulatory, Other Pre-Announcement

Context Therapeutics® Amends Cash Guidance, Extends Runway Into Q1 2024

Published: 09/27/2022 12:01 GMT
Context Therapeutics Inc (CNTX) - Context Therapeutics® Amends Cash Guidance, Extends Runway Into Q1 2024.
Context Therapeutics - Plans to Defer Noncritical Research and Development Activities, Reduce Future Overhead, Infrastructure Expenditures.
Context Therapeutics - Prioritizing Onapristone Extended Release (ona-xr) Elona Phase 1b/2 Clinical Trial, Claudin 6 (cldn6) Program.
Context Therapeutics - Anticipates Nomination of Cldn6xcd3 Bispecific Monoclonal Antibody Development Candidate With Integral Molecular in Q4 2022.
Context Therapeutics - Ind Submission for Cldn6 is Planned in Q1 2024.
Context Therapeutics - Remains on Track to Initiate Elona Clinical Trial in Q4 2022 and to Report Phase 1b Data in Q4 2023.
Context Therapeutics - Anticipates Sharing Preliminary Data From Phase 2 Clinical Trials in Granulosa Cell Tumors, Endometrial Cancer in Nov 2022.
Context Therapeutics - Anticipates Sharing Preliminary Data From Phase 2 Clinical Trial in Breast Cancer in Dec 2022.
Context Therapeutics - Will Continue to Provide Access to Ona-xr Through Company's Ongoing Investigator-sponsored Trials.